Inflammation and prostate cancer: friends or foe?

Inflammation Research

Volumn 64, Issue 5, 2015, Pages 275-286

  Taverna, Gianluigi ^a   Pedretti, Elisa ^a   Di Caro, Giuseppe ^a   Borroni, Elena Monica ^b   Marchesi, Federica ^a   Grizzi, Fabio ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Cancer; Chemokines; Immunity; Prostate

Indexed keywords

CHEMOKINE;

ADAPTIVE IMMUNITY; HUMAN; IMMUNOLOGY; INFLAMMATION; INNATE IMMUNITY; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

ADAPTIVE IMMUNITY; CHEMOKINES; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MALE; PROSTATIC NEOPLASMS;

EID: 84940003638     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-015-0812-2     Document Type: Review

References (135)

1. Shukla ME, Yu C, Reddy CA, Stephans KL, Klein EA, Abdel-Wahab M, et al. Evaluation of the current prostate cancer staging system based on cancer-specific mortality in the surveillance, epidemiology, and end results database. Clinical Genitourin Cancer. 2015;13(1):17–21 (PubMed PMID: 25571871).
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29 (PubMed PMID: 24399786).
3. Loeb S, Catalona WJ. Prostate-specific antigen in clinical practice. Cancer Lett. 2007;249(1):30–9 (PubMed PMID: 17258389).
4. Loeb S, Gashti SN, Catalona WJ. Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA). Urol Oncol. 2009;27(1):64–6 (PubMed PMID: 19111800).
5. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–8 (PubMed PMID: 19297566).
6. Presti JC Jr. Prostate biopsy strategies. Nat Clin Prac Urol. 2007;4(9):505–11 (PubMed PMID: 17823604).
7. Taverna G, Maffezzini M, Benetti A, Seveso M, Giusti G, Graziotti P. A single injection of lidocaine as local anesthesia for ultrasound guided needle biopsy of the prostate. J Urol. 2002;167(1):222–3 (PubMed PMID: 11743310).
8. Scattoni V, Maccagnano C, Capitanio U, Gallina A, Briganti A, Montorsi F. Random biopsy: when, how many and where to take the cores?. World J Urol. 2014;32(4):859–69 (PubMed PMID: 24908067).
9. Egevad L. Recent trends in Gleason grading of prostate cancer: I. Pattern interpretation. Anal Quant Cytol Histol/Int Acad Cytol Am Soc Cytol. 2008;30(4):190–8. (PubMed PMID: 18773736).
10. Rubin MA. Targeted therapy of cancer: new roles for pathologists–prostate cancer. Modern Pathol: Off J US Can Acad Pathol, Inc. 2008;21(Suppl 2):S44–55 (PubMed PMID: 18437173).
11. McDunn JE, Li Z, Adam KP, Neri BP, Wolfert RL, Milburn MV, et al. Metabolomic signatures of aggressive prostate cancer. Prostate. 2013;73(14):1547–60 (PubMed PMID: 23824564).
12. Schmid M, Hansen J, Rink M, Fisch M, Chun F. The development of nomograms for stratification of men at risk of prostate cancer prior to prostate biopsy. Biomark Med. 2013;7(6):843–50 (PubMed PMID: 24266817).
13. Dimakakos A, Armakolas A, Koutsilieris M. Novel tools for prostate cancer prognosis, diagnosis, and follow-up. BioMed Res Int. 2014;2014:890697 (PubMed PMID: 24877145. Pubmed Central PMCID: 4024423).
14. Valdes-Mora F, Clark SJ. Prostate cancer epigenetic biomarkers: next-generation technologies. Oncogene. 2014;0 (PubMed PMID: 24837368).
15. Qu M, Ren SC, Sun YH. Current early diagnostic biomarkers of prostate cancer. Asian J Androl. 2014;16(4):549–54 (PubMed PMID: 24830695).
16. Klotz L. Prostate cancer overdiagnosis and overtreatment. Curr Opin Endocrinol Diabetes Obes. 2013;20(3):204–9 (PubMed PMID: 23609043).
17. Veeranki S. Role of inflammasomes and their regulators in prostate cancer initiation, progression and metastasis. Cell Mol Biol Lett. 2013;18(3):355–67 (PubMed PMID: 23793845).
18. Orsted DD, Bojesen SE. The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol. 2013;10(1):49–54 (PubMed PMID: 23165396).
19. Nakai Y, Nonomura N. Inflammation and prostate carcinogenesis. Int J Urol: Off J Jpn Urol Assoc. 2013;20(2):150–60 (PubMed PMID: 22852773).
20. Taverna G, Seveso M, Giusti G, Hurle R, Graziotti P, Stifter S, et al. Senescent remodeling of the innate and adaptive immune system in the elderly men with prostate cancer. Curr Gerontol Geriatr Res. 2014;2014:478126 (PubMed PMID: 24772169. Pubmed Central PMCID: 3977481).
21. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7(4):256–69 (PubMed PMID: 17384581. Pubmed Central PMCID: 3552388).
22. Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, et al. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res. 2013;73(9):2718–36 (PubMed PMID: 23610450. Pubmed Central PMCID: 3644021).
23. Montironi R, Lopez-Beltran A, Mazzucchelli R, Scarpelli M, Galosi AB, Cheng L. Contemporary update on pathology-related issues on routine workup of prostate biopsy: sectioning, tumor extent measurement, specimen orientation, and immunohistochemistry. Anal Quant Cytol Histol/Int Acad Cytol Am Soc Cytol. 2014;36(2):61–70 (PubMed PMID: 24902358).
24. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature. 2010;464(7286):302–5 (PubMed PMID: 20220849. Pubmed Central PMCID: 2866639).
25. Gurel B, Lucia MS, Thompson IM, Jr., Goodman PJ, Tangen CM, Kristal AR, et al. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2014;23(5):847–56. (PubMed PMID: 24748218. Pubmed Central PMCID: 4012292).
26. Klinke DJ 2nd. An evolutionary perspective on anti-tumor immunity. Front Oncol. 2012;2:202 (PubMed PMID: 23336100. Pubmed Central PMCID: 3541690).
27. Chiarugi P, Paoli P, Cirri P. Tumor microenvironment and metabolism in prostate cancer. Semin Oncol. 2014;41(2):267–80 (PubMed PMID: 24787298).
28. Goldstein AS, Witte ON. Does the microenvironment influence the cell types of origin for prostate cancer? Genes Dev. 2013;27(14):1539–44 (PubMed PMID: 23873937).
29. Sfanos KS, Hempel HA, De Marzo AM. The role of inflammation in prostate cancer. Adv Exp Med Biol. 2014;816:153–81 (PubMed PMID: 24818723).
30. Vykhovanets EV, Maclennan GT, Vykhovanets OV, Gupta S. IL-17 expression by macrophages is associated with proliferative inflammatory atrophy lesions in prostate cancer patients. Int J Clin Exp Pathol. 2011;4(6):552–65. (PubMed PMID: 21904631. Pubmed Central PMCID: 3160607. Epub 2011/09/10. eng).
31. Fang LY, Izumi K, Lai KP, Liang L, Li L, Miyamoto H, et al. Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling. Cancer Res. 2013;73(18):5633–46 (PubMed PMID: 23878190. PubMed Central PMCID: 3833080).
32. Okada K, Kojima M, Naya Y, Kamoi K, Yokoyama K, Takamatsu T, et al. Correlation of histological inflammation in needle biopsy specimens with serum prostate-specific antigen levels in men with negative biopsy for prostate cancer. Urology. 2000;55(6):892–8 (PubMed PMID: 10840104. Epub 2000/06/07. eng).
33. Pittoni P, Colombo MP. The dark side of mast cell-targeted therapy in prostate cancer. Cancer Res. 2012;72(4):831–5 (PubMed PMID: 22307838. Epub 2012/02/07. eng).
34. Taverna G, Giusti G, Seveso M, Hurle R, Colombo P, Stifter S, et al. Mast cells as a potential prognostic marker in prostate cancer. Dis Markers. 2013;35(6):711–20 (PubMed PMID: 24324287. Pubmed Central PMCID: 3844173).
35. Globa T, Saptefrti L, Ceausu RA, Gaje P, Cimpean AM, Raica M. Mast cell phenotype in benign and malignant tumors of the prostate. Pol J Pathol: Off J Pol Soc Pathol. 2014;65(2):147–53 (PubMed PMID: 25119176).
36. Frankel TL, Burns W, Riley J, Morgan RA, Davis JL, Hanada K, et al. Identification and characterization of a tumor infiltrating CD56(+)/CD16(−) NK cell subset with specificity for pancreatic and prostate cancer cell lines. Cancer Immunol Immunother. 2010;59(12):1757–69 PubMed PMID: 20734041. Epub 2010/08/25. eng.
37. Kryvenko ON, Jankowski M, Chitale DA, Tang D, Rundle A, Trudeau S, et al. Inflammation and preneoplastic lesions in benign prostate as risk factors for prostate cancer. Mod Pathol: Off J US Can Acad Pathol, Inc. 2012;25(7):1023–32 (PubMed PMID: 22460812. Epub 2012/03/31. eng).
38. Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology. 2012;60(1):199–215 (PubMed PMID: 22212087. Epub 2012/01/04. eng).
39. Flammiger A, Bayer F, Cirugeda-Kuhnert A, Huland H, Tennstedt P, Simon R, et al. Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. Apmis. 2012;120(11):901–8 (PubMed PMID: 23009114. Epub 2012/09/27. eng).
40. McDowell KL, Begley LA, Mor-Vaknin N, Markovitz DM, Macoska JA. Leukocytic promotion of prostate cellular proliferation. Prostate. 2010;70(4):377–89 (Pubmed Central PMCID: 3167472. Epub 2009/10/30. eng).
41. Liu Y, Saeter T, Vlatkovic L, Servoll E, Waaler G, Axcrona U, et al. Dendritic and lymphocytic cell infiltration in prostate carcinoma. Histol Histopathol. 2013;28(12):1621–8 (PubMed PMID: 23729368).
42. Hussein MR, Al-Assiri M, Musalam AO. Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma. Exp Mol Pathol. 2009;86(2):108–13 (PubMed PMID: 19111537).
43. De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schroder F, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol. 2011;60(1):106–17 (PubMed PMID: 21497433).
44. Lakshmi Narendra B, Eshvendar Reddy K, Shantikumar S, Ramakrishna S. Immune system: a double-edged sword in cancer. Inflamm Res: Off J Eur Hist Res Soc [et al]. 2013;62(9):823–34 (PubMed PMID: 23868500).
45. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44 (PubMed PMID: 18650914).
46. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7 (PubMed PMID: 12490959. Pubmed Central PMCID: 2803035).
47. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889–96 (PubMed PMID: 20856220).
48. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22(2):231–7 (PubMed PMID: 20144856).
49. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, et al. Macrophage polarization in tumour progression. Semin Cancer Biol. 2008;18(5):349–55 (PubMed PMID: 18467122).
50. Lanciotti M, Masieri L, Raspollini MR, Minervini A, Mari A, Comito G, et al. The role of M1 and M2 macrophages in prostate cancer in relation to extracapsular tumor extension and biochemical recurrence after radical prostatectomy. BioMed Res Int. 2014;2014:486798 (PubMed PMID: 24738060. Pubmed Central PMCID: 3967497).
51. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999;155(6):1985–92 (PubMed PMID: 10595928. Pubmed Central PMCID: 1866955).
52. Comito G, Giannoni E, Segura CP, Barcellos-de-Souza P, Raspollini MR, Baroni G, et al. Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression. Oncogene. 2014;33(19):2423–31 (PubMed PMID: 23728338).
53. Xu J, Escamilla J, Mok S, David J, Priceman S, West B, et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 2013;73(9):2782–94 (PubMed PMID: 23418320).
54. Fujii T, Shimada K, Asai O, Tanaka N, Fujimoto K, Hirao K, et al. Immunohistochemical analysis of inflammatory cells in benign and precancerous lesions and carcinoma of the prostate. Pathobiol: J Immunopathol Mol Cell Biol. 2013;80(3):119–26 (PubMed PMID: 23328608).
55. Kakehi Y, Segawa T, Wu XX, Kulkarni P, Dhir R, Getzenberg RH. Down-regulation of macrophage inhibitory cytokine-1/prostate derived factor in benign prostatic hyperplasia. Prostate. 2004;59(4):351–6 (PubMed PMID: 15065082).
56. Dubey S, Vanveldhuizen P, Holzbeierlein J, Tawfik O, Thrasher JB, Karan D. Inflammation-associated regulation of the macrophage inhibitory cytokine (MIC-1) gene in prostate cancer. Oncol Lett. 2012;3(5):1166–70 (PubMed PMID: 22783412. Pubmed Central PMCID: 3389684).
57. Pickup M, Novitskiy S, Moses HL. The roles of TGFbeta in the tumour microenvironment. Nat Rev Cancer. 2013;13(11):788–99 (PubMed PMID: 24132110).
58. Vanhara P, Hampl A, Kozubik A, Soucek K. Growth/differentiation factor-15: prostate cancer suppressor or promoter? Prostate Cancer Prostatic Dis. 2012;15(4):320–8 (PubMed PMID: 22370725).
59. Wang T, Welte T. Role of natural killer and Gamma-delta T cells in West Nile virus infection. Viruses. 2013;5(9):2298–310 (PubMed PMID: 24061543. Pubmed Central PMCID: 3798903).
60. Yuan H, Hsiao YH, Zhang Y, Wang J, Yin C, Shen R, et al. Destructive impact of T-lymphocytes, NK and Mast cells on basal cell layers: implications for tumor invasion. BMC Cancer. 2013;13:258 (PubMed PMID: 23705594. Pubmed Central PMCID: 3722065).
61. Jaillon S, Galdiero MR, Del Prete D, Cassatella MA, Garlanda C, Mantovani A. Neutrophils in innate and adaptive immunity. Semin Immunopathol. 2013;35(4):377–94 (PubMed PMID: 23553214).
62. Fujita K, Imamura R, Tanigawa G, Nakagawa M, Hayashi T, Kishimoto N, et al. Low serum neutrophil count predicts a positive prostate biopsy. Prostate Cancer Prostatic Dis. 2012;15(4):386–90 (PubMed PMID: 22777394).
63. Bekes EM, Schweighofer B, Kupriyanova TA, Zajac E, Ardi VC, Quigley JP, et al. Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. Am J Pathol. 2011;179(3):1455–70 (PubMed PMID: 21741942. Pubmed Central PMCID: 3157227).
64. Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, et al. Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncologist. 2012;17(12):1508–14 (PubMed PMID: 22971522. Pubmed Central PMCID: 3528383).
65. Raval RR, Sharabi AB, Walker AJ, Drake CG, Sharma P. Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer. 2014;2:14 (PubMed PMID: 24883190. Pubmed Central PMCID: 4039332).
66. McArdle PA, Canna K, McMillan DC, McNicol AM, Campbell R, Underwood MA. The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer. 2004;91(3):541–3 (PubMed PMID: 15266325. Pubmed Central PMCID: 2409839).
67. Yuan H, Wei X, Zhang G, Li C, Zhang X, Hou J. B7-H3 over expression in prostate cancer promotes tumor cell progression. J Urol. 2011;186(3):1093–9 (PubMed PMID: 21784485).
68. + CD127−) after cryosurgery in prostate cancer. Asian J Androl. 2013;15(4):461–5 (PubMed PMID: 23728588. Pubmed Central PMCID: 3739231).
69. + CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol. 2006;177(10):7398–405 (PubMed PMID: 17082659).
70. Yokokawa J, Cereda V, Remondo C, Gulley JL, Arlen PM, Schlom J, et al. Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2008;14(4):1032–40 (PubMed PMID: 18281535).
71. Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clinical Cancer Research: Off J Am Assoc Cancer Res. 2008;14(11):3254–61 (PubMed PMID: 18519750. Pubmed Central PMCID: 3082357).
72. Zou L, Barnett B, Safah H, Larussa VF, Evdemon-Hogan M, Mottram P, et al. Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res. 2004;64(22):8451–5 (PubMed PMID: 15548717).
73. Davidsson S, Ohlson AL, Andersson SO, Fall K, Meisner A, Fiorentino M, et al. CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal prostate cancer. Modern Pathol: Off J US Can Acad Pathol, Inc. 2013;26(3):448–55 (PubMed PMID: 23041830).
74. Gannon PO, Alam Fahmy M, Begin LR, Djoukhadjian A, Filali-Mouhim A, Lapointe R, et al. Presence of prostate cancer metastasis correlates with lower lymph node reactivity. Prostate. 2006;66(16):1710–20 (PubMed PMID: 16955408).
75. Vindrieux D, Escobar P, Lazennec G. Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer. 2009;16(3):663–73 (PubMed PMID: 19556286).
76. Balkwill FR. The chemokine system and cancer. J Pathol. 2012;226(2):148–57 (PubMed PMID: 21989643).
77. Vendramini-Costa DB, Carvalho JE. Molecular link mechanisms between inflammation and cancer. Curr Pharm Des. 2012;18(26):3831–52 (PubMed PMID: 22632748).
78. Salazar N, Castellan M, Shirodkar SS, Lokeshwar BL. Chemokines and chemokine receptors as promoters of prostate cancer growth and progression. Critical Rev Eukaryot Gene Expr. 2013;23(1):77–91 (PubMed PMID: 23557339. Pubmed Central PMCID: 3736734).
79. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014–22 (PubMed PMID: 24048123. Pubmed Central PMCID: 4118725).
80. Bonecchi R, Galliera E, Borroni EM, Corsi MM, Locati M, Mantovani A. Chemokines and chemokine receptors: an overview. Front Biosci. 2009;14:540–51 (PubMed PMID: 19273084).
81. Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010;21(1):27–39 (PubMed PMID: 20004131).
82. Chow MT, Luster AD. Chemokines in cancer. Cancer Immunol Res. 2014;2(12):1125–31 (PubMed PMID: 25480554. Pubmed Central PMCID: 4258879).
83. Allavena P, Germano G, Marchesi F, Mantovani A. Chemokines in cancer related inflammation. Exp Cell Res. 2011;317(5):664–73 (PubMed PMID: 21134366).
84. Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I. Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci. 2007;98(11):1652–8 (PubMed PMID: 17894551).
85. Ben-Baruch A. Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis. 2008;25(4):345–56 (PubMed PMID: 17891505).
86. Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 2011;11(9):597–606 (PubMed PMID: 21866172).
87. Wu Q, Dhir R, Wells A. Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion. Mol Cancer. 2012;11:3 (PubMed PMID: 22236567. Pubmed Central PMCID: 3320557).
88. Gillies K, Wertman J, Charette N, Dupre DJ. Anterograde trafficking of CXCR4 and CCR2 receptors in a prostate cancer cell line. Cell Physiol Biochem: Int J Exper Cell Physiol Biochem Pharmacol. 2013;32(1):74–85 (PubMed PMID: 23839224).
89. Kato T, Fujita Y, Nakane K, Mizutani K, Terazawa R, Ehara H, et al. CCR1/CCL5 interaction promotes invasion of taxane-resistant PC3 prostate cancer cells by increasing secretion of MMPs 2/9 and by activating ERK and Rac signaling. Cytokine. 2013;64(1):251–7 (PubMed PMID: 23876400).
90. Zhu F, Liu P, Li J, Zhang Y. Eotaxin-1 promotes prostate cancer cell invasion via activation of the CCR3-ERK pathway and upregulation of MMP-3 expression. Oncol Rep. 2014;31(5):2049–54 (PubMed PMID: 24604010).
91. Lam C, Pavel MA, Kashyap P, Salehi-Najafabadi Z, Valentino V, Yu Y. Detection of CXCR2 cytokine receptor surface expression using immunofluorescence. Methods Mol Biol. 2014;1172:193–200 (PubMed PMID: 24908306).
92. Peng C, Zhou K, An S, Yang J. The effect of CCL19/CCR7 on the proliferation and migration of cell in prostate cancer. Tumour Biol: J Int Soc Oncodevelop Biol Med. 2015;36(1):329–35 (PubMed PMID: 25256673).
93. Maxwell PJ, Neisen J, Messenger J, Waugh DJ. Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells. Oncotarget. 2014;5(13):4895–908 (PubMed PMID: 24970800. Pubmed Central PMCID: 4148108).
94. Culig Z. CXCL8, an underestimated “bad guy” in prostate cancer. Eur Urol. 2013;64(2):189–90 (discussion 90-2. PubMed PMID: 23000087).
95. Benelli R, Stigliani S, Minghelli S, Carlone S, Ferrari N. Impact of CXCL1 overexpression on growth and invasion of prostate cancer cell. Prostate. 2013;73(9):941–51 (PubMed PMID: 23334998).
96. Lin TH, Liu HH, Tsai TH, Chen CC, Hsieh TF, Lee SS, et al. CCL2 increases alphavbeta3 integrin expression and subsequently promotes prostate cancer migration. Biochim Biophys Acta. 2013;1830(10):4917–27 (PubMed PMID: 23845726).
97. Fang LY, Izumi K, Lai KP, Liang L, Li L, Miyamoto H, et al. Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling. Cancer research. 2013;73(18):5633–46 (PubMed PMID: 23878190. Pubmed Central PMCID: 3833080).
98. Ammirante M, Shalapour S, Kang Y, Jamieson CA, Karin M. Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts. Proc Natl Acad Sci USA. 2014;111(41):14776–81 (PubMed PMID: 25267627. Pubmed Central PMCID: 4205637).
99. Chen G, Liang YX, Zhu JG, Fu X, Chen YF, Mo RJ, et al. CC chemokine ligand 18 correlates with malignant progression of prostate cancer. BioMed Res Int. 2014;2014:230183 (PubMed PMID: 25197632. Pubmed Central PMCID: 4150478).
100. Singh RK, Lokeshwar BL. The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Res. 2011;71(9):3268–77 (PubMed PMID: 21398406. Pubmed Central PMCID: 3085571).
101. Ellem SJ, Taylor RA, Furic L, Larsson O, Frydenberg M, Pook D, et al. A pro-tumourigenic loop at the human prostate tumour interface orchestrated by oestrogen, CXCL12 and mast cell recruitment. J Pathol. 2014;234(1):86–98 (PubMed PMID: 25042571).
102. Lin WJ, Izumi K. Androgen receptor, ccl2, and epithelial-mesenchymal transition: A dangerous affair in the tumor microenvironment. Oncoimmunology. 2014;3:e27871 (PubMed PMID: 25339999. Pubmed Central PMCID: 4203538).
103. Izumi K, Fang LY, Mizokami A, Namiki M, Li L, Lin WJ, et al. Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. EMBO Mol Med. 2013;5(9):1383–401 (PubMed PMID: 23982944. Pubmed Central PMCID: 3799493).
104. Bao BY, Yao J, Lee YF. 1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis. 2006;27(9):1883–93 (PubMed PMID: 16624828).
105. Velonas VM, Woo HH, dos Remedios CG, Assinder SJ. Current status of biomarkers for prostate cancer. Int J Mol Sci. 2013;14(6):11034–60 (PubMed PMID: 23708103. Pubmed Central PMCID: 3709717).
106. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol. 2003;21(2):383–91 (PubMed PMID: 12525533).
107. Makarov DV, Loeb S, Getzenberg RH, Partin AW. Biomarkers for prostate cancer. Annu Rev Med. 2009;60:139–51 (PubMed PMID: 18947298).
108. Tsaur I, Noack A, Makarevic J, Oppermann E, Waaga-Gasser AM, Gasser M, et al. CCL2 chemokine as a potential biomarker for prostate cancer: a pilot study. Cancer Res Treat: Off J Korean Cancer Assoc. 2014. doi:10.4143/crt.2014.015 (PubMed PMID: 25483747).
109. Xu Y, Zhang L, Sun SK, Zhang X. CC chemokine ligand 18 and IGF-binding protein 6 as potential serum biomarkers for prostate cancer. Tohoku J Exper Med. 2014;233(1):25–31 (PubMed PMID: 24747338).
110. Sharma J, Gray KP, Harshman LC, Evan C, Nakabayashi M, Fichorova R, et al. Elevated IL-8, TNF-alpha, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Prostate. 2014;74(8):820–8 (PubMed PMID: 24668612).
111. Agarwal M, He C, Siddiqui J, Wei JT, Macoska JA. CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer. Prostate. 2013;73(6):573–81 (PubMed PMID: 23059958. Pubmed Central PMCID: 3594486).
112. Miyake M, Lawton A, Goodison S, Urquidi V, Rosser CJ. Chemokine (C-X-C motif) ligand 1 (CXCL1) protein expression is increased in high-grade prostate cancer. Pathol Res Pract. 2014;210(2):74–8 (PubMed PMID: 24252309).
113. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, et al. Human prostate cancer risk factors. Cancer. 2004;101(10 Suppl):2371–490 (PubMed PMID: 15495199).
114. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 2008;68(3):927–36 (PubMed PMID: 18245496).
115. Isman FK, Kucukgergin C, Dasdemir S, Cakmakoglu B, Sanli O, Seckin S. Association between SDF1-3′A or CXCR4 gene polymorphisms with predisposition to and clinicopathological characteristics of prostate cancer with or without metastases. Mol Biol Rep. 2012;39(12):11073–9 (PubMed PMID: 23053994).
116. Mandal RK, Agrawal T, Mittal RD. Genetic variants of chemokine CCL2 and chemokine receptor CCR2 genes and risk of prostate cancer. Tumour Biol: J Int Soc Oncodevelopment Biol Med. 2015;36(1):375–81 (PubMed PMID: 25266801).
117. Kirk PS, Koreckij T, Nguyen HM, Brown LG, Snyder LA, Vessella RL, et al. Inhibition of CCL2 signaling in combination with docetaxel treatment has profound inhibitory effects on prostate cancer growth in bone. Int J Mol Sci. 2013;14(5):10483–96 (PubMed PMID: 23698775. Pubmed Central PMCID: 3676850).
118. Zhang J, Patel L, Pienta KJ. Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. Prog Mol Biol Transl Sci. 2010;95:31–53 (PubMed PMID: 21075328. Pubmed Central PMCID: 3197817).
119. Zhang J, Lu Y, Pienta KJ. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst. 2010;102(8):522–8 (PubMed PMID: 20233997. Pubmed Central PMCID: 2857800).
120. Arnatt CK, Adams JL, Zhang Z, Haney KM, Li G, Zhang Y. Design, syntheses, and characterization of piperazine based chemokine receptor CCR5 antagonists as anti prostate cancer agents. Bioorg Med Chem Lett. 2014;24(10):2319–23 (PubMed PMID: 24731275).
121. Arnatt CK, Zaidi SA, Zhang Z, Li G, Richardson AC, Ware JL, et al. Design, syntheses, and characterization of pharmacophore based chemokine receptor CCR5 antagonists as anti prostate cancer agents. Eur J Med Chem. 2013;69:647–58 (PubMed PMID: 24095757).
122. Bhardwaj A, Srivastava SK, Singh S, Arora S, Tyagi N, Andrews J, et al. CXCL12/CXCR4 signaling counteracts docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIM domain kinase 1. Oncotarget. 2014;5(22):11490–500 (PubMed PMID: 25359780. Pubmed Central PMCID: 4294337).
123. Domanska UM, Timmer-Bosscha H, Nagengast WB, Oude Munnink TH, Kruizinga RC, Ananias HJ, et al. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia. 2012;14(8):709–18 (PubMed PMID: 22952424. Pubmed Central PMCID: 3431178).
124. Rhee YH, Chung PS, Kim SH, Ahn JC. CXCR4 and PTEN are involved in the anti-metastatic regulation of anethole in DU145 prostate cancer cells. Biochem Biophys Res Commun. 2014;447(4):557–62 (PubMed PMID: 24525130).
125. Mackinnon AC, Yan BC, Joseph LJ, Al-Ahmadie HA. Molecular biology underlying the clinical heterogeneity of prostate cancer: an update. Arch Pathol Lab Med. 2009;133(7):1033–40 (PubMed PMID: 19642730. Epub 2009/08/01. eng).
126. Gerlinger M, Catto JW, Orntoft TF, Real FX, Zwarthoff EC, Swanton C. Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications. Eur Urol. 2015;67(4):729–37 (PubMed PMID: 24836153).
127. Demichelis F, Stanford JL. Genetic predisposition to prostate cancer: Update and future perspectives. Urol Oncol. 2015;33(2):75–84 (PubMed PMID: 24996773).
128. Franco OE, Hayward SW. Targeting the tumor stroma as a novel therapeutic approach for prostate cancer. Adv Pharmacol. 2012;65:267–313 (PubMed PMID: 22959029. Epub 2012/09/11. eng).
129. Iacopino F, Angelucci C, Sica G. Interactions between normal human fibroblasts and human prostate cancer cells in a co-culture system. Anticancer Res. 2012;32(5):1579–88 (PubMed PMID: 22593435. Epub 2012/05/18. eng).
130. Parrinello S, Coppe JP, Krtolica A, Campisi J. Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J Cell Sci. 2005;118(Pt 3):485–96 (PubMed PMID: 15657080. Epub 2005/01/20. eng).
131. Gharaee-Kermani M, Kasina S, Moore BB, Thomas D, Mehra R, Macoska JA. CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis. PloS one. 2012;7(11):e49278 (PubMed PMID: 23173053. Pubmed Central PMCID: 3500280).
132. Mimeault M, Batra SK. Development of animal models underlining mechanistic connections between prostate inflammation and cancer. World J Clin Oncol. 2013;4(1):4–13 (PubMed PMID: 23539141. Pubmed Central PMCID: 3609015).
133. Gutkin DW, Shurin MR. Clinical evaluation of systemic and local immune responses in cancer: time for integration. Cancer Immunol Immunother. 2014;63(1):45–57 (PubMed PMID: 24100804. Pubmed Central PMCID: 4018188).
134. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306 (PubMed PMID: 22419253).
135. Vignozzi L, Maggi M. Prostate cancer: intriguing data on inflammation and prostate cancer. Nat Rev Urol. 2014;11(7):369–70 (PubMed PMID: 24980193).